Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

ABLX

Ablynx NV (ABLX)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABLX
DataOraFonteTitoloSimboloCompagnia
19/06/201807:00GlobeNewswireSANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURENASDAQ:ABLXAblynx NV ADS (delisted)
28/05/201807:05GlobeNewswirePUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...NASDAQ:ABLXAblynx NV ADS (delisted)
25/05/201819:00GlobeNewswireNOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020NASDAQ:ABLXAblynx NV ADS (delisted)
17/05/201807:00GlobeNewswireABLYNX ANNOUNCES WARRANT EXERCISENASDAQ:ABLXAblynx NV ADS (delisted)
14/05/201808:57Dow Jones NewsSanofi-Ablynx Deal Goes AheadNASDAQ:ABLXAblynx NV ADS (delisted)
14/05/201808:00GlobeNewswireSANOFI AND ABLYNX ANNOUNCE THE SUCCESSFUL RESULTS OF THE INITIAL TENDER OFFER PERIOD FOR ABLYNX AND COMMENCEMENT OF SQUEEZE-O...NASDAQ:ABLXAblynx NV ADS (delisted)
30/04/201807:00GlobeNewswireABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIb RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171NASDAQ:ABLXAblynx NV ADS (delisted)
29/03/201807:00GlobeNewswirePREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018NASDAQ:ABLXAblynx NV ADS (delisted)
26/03/201807:00GlobeNewswireABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSNASDAQ:ABLXAblynx NV ADS (delisted)
02/03/201807:00GlobeNewswireABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTIONNASDAQ:ABLXAblynx NV ADS (delisted)
01/03/201811:19Dow Jones NewsSanofi Receives Antitrust Clearances in U.S., Germany for Ablynx AcquisitionNASDAQ:ABLXAblynx NV ADS (delisted)
28/02/201807:00GlobeNewswireABLYNX ANNOUNCES CONVERSION OF BONDSNASDAQ:ABLXAblynx NV ADS (delisted)
22/02/201807:00GlobeNewswireABLYNX ANNOUNCES 2017 FULL YEAR RESULTSNASDAQ:ABLXAblynx NV ADS (delisted)
16/02/201807:00GlobeNewswireABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATESNASDAQ:ABLXAblynx NV ADS (delisted)
07/02/201807:00GlobeNewswireABLYNX ANNOUNCES BOARD CHANGESNASDAQ:ABLXAblynx NV ADS (delisted)
30/01/201809:02Dow Jones NewsSanofi To Acquire Belgian Biotech -- WSJNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201811:59Dow Jones NewsNovo Nordisk Confirms It Will Not Make Revised Bid for AblynxNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201811:54Dow Jones NewsSanofi to Buy Ablynx for $4.85 Billion -- UpdateNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201809:06Dow Jones NewsSanofi to Acquire Ablynx for EUR3.9 BillionNASDAQ:ABLXAblynx NV ADS (delisted)
29/01/201808:19GlobeNewswireSANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLIONNASDAQ:ABLXAblynx NV ADS (delisted)
24/01/201807:00GlobeNewswireABLYNX APPOINTS DR ROBERT FRIESEN AS CHIEF SCIENTIFIC OFFICERNASDAQ:ABLXAblynx NV ADS (delisted)
22/01/201807:00GlobeNewswireABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDSNASDAQ:ABLXAblynx NV ADS (delisted)
09/01/201809:02Dow Jones NewsDrug Firm Rejects $3.13 Billion Offer From Novo Nordisk -- WSJNASDAQ:ABLXAblynx NV ADS (delisted)
08/01/201813:25GlobeNewswireABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUT...NASDAQ:ABLXAblynx NV ADS (delisted)
08/01/201808:30Dow Jones NewsBelgium's Ablynx Rejects EUR2.6 Billion Bid From Novo NordiskNASDAQ:ABLXAblynx NV ADS (delisted)
04/01/201807:00GlobeNewswireABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCENASDAQ:ABLXAblynx NV ADS (delisted)
27/12/201707:00GlobeNewswireNOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTIONNASDAQ:ABLXAblynx NV ADS (delisted)
21/12/201707:00GlobeNewswireABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMABNASDAQ:ABLXAblynx NV ADS (delisted)
12/12/201713:40GlobeNewswireABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTPNASDAQ:ABLXAblynx NV ADS (delisted)
07/12/201707:00GlobeNewswireABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLO...NASDAQ:ABLXAblynx NV ADS (delisted)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABLX
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network